secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001815776-25-000069
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENZ Therapeutics Q3 2025 net loss $16.7M; VIZZ launch with 5K+ prescriptions in October
--------------------------------------------------------------------------------

- Net loss $16.7M ($0.59/share) vs $10.2M in Q3 2024; R&D spend down to $3.8M.
- SG&A expenses surged to $27.6M ($6.5M Q3 2024) from commercial launch infrastructure.
- Pro forma cash $324M after $123.5M ATM raise in Oct 2025, extending runway to post-launch cash flow positive.
- VIZZ (aceclidine) launched Oct 2025 with >2,500 unique prescribers and >5,000 prescriptions filled through Oct.
- Partnered with Sarah Jessica Parker for DTC campaign starting Q1 2026; Canada deal with Théa worth >$70M in milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/0001815776-25-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/lenz-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001815776-25-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer